Aims To compare and rank the myopia control effects of different light wavelengths in children using a systematic review and Bayesian network meta-analysis (Bayesian NMA). Methods The review protocol was registered with PROSPERO. We searched PubMed, EMBASE and MEDLINE for relevant clinical and animal studies published as of 2 February 2023. We included studies comparing red, violet or full-spectrum light with controls. Data extracted included descriptive statistics and study outcomes (axial length (AL) elongation and progression of spherical equivalent (SE) refraction). After quality assessment, estimates of treatment effect outcomes (mean differences (MDs) and 95% CIs) were first pooled for the animal and clinical studies in a traditional meta-analysis. To compare and rank the different light wavelengths, the Bayesian NMA was then conducted for all the included clinical studies (12 studies) and separately for only randomised controlled trials (8 studies). MDs, 95% credible intervals (CrIs) and ranks of the various light wavelengths were estimated in the Bayesian NMA. Results When all clinical studies were included in the Bayesian NMA (12 studies), only red-light significantly slowed AL elongation, MD (95% CrI), −0.38 mm (−0.59 mm to −0.16 mm)/year and SE refraction progression, 0.72D (0.35D to 1.10D)/year compared with controls. It remained the only significant intervention when effect sizes from only RCTs (eight studies) were separately combined, (−0.28 mm (−0.40 mm to −0.15 mm)/year and 0.57D (0.22D to 0.92D)/year, for AL and SE refraction, respectively). Conclusion Myopia control efficacy varied among different wavelengths of light, with red light ranked as the most effective. PROSPERO registration number Clinical studies: CRD42022368998; animal studies: CRD42022368671. All data relevant to the study are included in the article or uploaded as supplementary information.

中文翻译：

---

光照射疗法控制近视：系统评价和贝叶斯网络荟萃分析


目的 通过系统评价和贝叶斯网络荟萃分析（贝叶斯 NMA）对不同光波长对儿童的近视控制效果进行比较和排名。方法 审查方案在 PROSPERO 注册。我们检索了 PubMed、EMBASE 和 MEDLINE，查找截至 2023 年 2 月 2 日发表的相关临床和动物研究。我们纳入了将红色、紫色或全光谱光与对照进行比较的研究。提取的数据包括描述性统计数据和研究结果（轴长 (AL) 伸长和球面等效 (SE) 屈光度的进展）。质量评估后，首先在传统荟萃分析中汇总动物和临床研究的治疗效果结果估计（平均差 (MD) 和 95% CI）。为了对不同的光波长进行比较和排序，对所有纳入的临床研究（12 项研究）和仅随机对照试验（8 项研究）分别进行了贝叶斯 NMA。在贝叶斯 NMA 中估计了 MD、95% 可信区间 (CrIs) 和各种光波长的等级。结果 当所有临床研究均纳入贝叶斯 NMA（12 项研究）时，只有红光显着减慢 AL 伸长、MD (95% CrI)、-0.38 毫米（-0.59 毫米至 -0.16 毫米）/年和 SE 屈光进展，与对照相比，0.72D（0.35D 至 1.10D）/年。当单独组合仅随机对照试验（八项研究）的效应大小时，它仍然是唯一显着的干预措施，（对于 AL，-0.28 毫米（-0.40 毫米至-0.15 毫米）/年和 0.57D（0.22D 至 0.92D）/年和 SE 折射）。结论 不同波长的光对近视的控制效果存在差异，以红光最为有效。 PROSPERO注册号临床研究：CRD42022368998；动物研究：CRD42022368671。与研究相关的所有数据都包含在文章中或作为补充信息上传。